Os efeitos adversos das fluoroquinolonas e o impacto das advertências da agência norte-americana de regulamentação de medicamentos (Food and Drug Administration - FDA) na prática clínica

• Autor(a) principal: VEIGA, Karoline Moreira
• Data de Publicação: 2021
• Outros Autores: SUGANUMA, Larissa Yuri
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Digital Unicesumar
• Texto Completo: http://rdu.unicesumar.edu.br/handle/123456789/7619
• topic: Fluoroquinolonas; Antibióticos; Avisos; Efeitos adversos; FDA; CNPQ::CIENCIAS DA SAUDE::MEDICINA

Fluoroquinolones are among the most prescribed antibiotics worldwide. Nevertheless, they can trigger severe adverse effects such as peripheral neuropathy, tendinopathies, cardiac arrhythmia, aortic aneurysms and alterations in the Central Nervous Systems (CNS) Toxicity is particularly higher on people over age 60, corticosteroides users, people with renal dysfunction and recipients of solid organ transplantation. Despite the recommendations and warnings by the Food and Drug Administration (FDA) of the United States, FQS continue to be largely prescribed in clinical practice. Methods: In order to identify the most updated research on this issue, the PUBMED database was largely used to select articles that were published in the last five years and were written in English. Results: From the 58 articles that have been identified, 33 were selected and 25 were ignored for not matching the focus of this study. Due to their adverse effects, FQS should not be considered for first-line treatment for uncomplicated urinary tract infection (UTI) or respiratory tract infections. Only due to refractoriness or allergy to medicines used in the first-line treatment should FQS be applied. Discussion: Considering the severity of adverse effects from FQS, new practical measures should be taken into account to help the development of a more appropriate prescription of antibiotics. By doing so, toxicity as well as antimicrobial resistance may be reduced.